Dr. Sarah Ibrahim serves as the Associate Director for Stakeholder and Global Engagement at the Office of Generic Drugs (OGD) within the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA). In this role, Dr. Ibrahim formulates strategies to address both current and emerging regulatory challenges related to the global generic drug industry. She founded OGD’s Global Affairs Program and the FDA Global Generic Drug Cluster, the first forum to bring together leading regulatory agencies worldwide. Additionally, Dr. Ibrahim initiated OGD’s Patient Engagement Program and launched its first Patient Listening Session series. Collaborating with other CDER and FDA offices, she facilitates stakeholder engagement on issues pertaining to the globalization of the generic pharmaceutical supply chain and the harmonization of regulatory standards for generic drugs.
Dr. Ibrahim earned her Ph.D. in Biopharmaceutics/Pharmaceutics from the University of Cincinnati’s College of Pharmacy and holds a B.S. in Pharmacy and Pharmaceutical Sciences from Cairo University, Egypt. She joined the FDA in 2014 as a scientific reviewer in the Office of Pharmaceutical Quality. Before her tenure at the FDA, Dr. Ibrahim accrued extensive experience in the U.S. pharmaceutical industry, focusing on pharmaceutical development. As an assistant professor, she was instrumental in establishing the pharmaceutical sciences department at New Jersey’s second pharmacy school, working alongside the founding faculty.
